RxDoctor Payments DataLook up a doctor →

Rohit Dwivedi, MD

Endocrinology · Surprise, AZNPI 1255398194

Payments from drug & device makers

$91,303in general payments, 2019–2025

Across 651 payments — averaging $140.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$37K
  • AbbVie$25K
  • Currax Pharmaceuticals LLC$14K
  • Kyowa Kirin, Inc.$7K
  • Novo Nordisk$1K
  • Amgen$794
  • plus $6K from 50 others

What the payments were for

  • Consulting fees$1,9653%
  • Speaking & faculty fees$56,38873%
  • Travel & lodging$7,1239%
  • Food & beverage$11,78915%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$161,190
Medicare patients
414
Services billed
1,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide148$211,587
JardianceEmpagliflozin130$201,854
OzempicSemaglutide99$179,366
TrulicityDulaglutide91$123,285
Bydureon BciseExenatide Microspheres83$119,851
ForteoTeriparatide12$82,248
FarxigaDapagliflozin Propanediol55$65,790
JanuviaSitagliptin Phosphate45$58,890
TradjentaLinagliptin56$52,622
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/745$41,898
Fiasp FlextouchInsulin Aspart (Niacinamide)33$38,314
Teriparatide11$29,500
Lantus SolostarInsulin Glargine,hum.Rec.Anlog170$26,663
RybelsusSemaglutide12$25,914
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog46$22,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog$485$424,165279 claims
Boehringer IngelheimJardiance, Tradjenta$177$254,475186 claims
Novo NordiskOzempic, Rybelsus, Novolog$1,402$207,446122 claims
AstraZenecaFarxiga$37,324$65,79055 claims
MerckJanuvia$24$58,89045 claims
Alvogen IncTeriparatide$18$29,50011 claims
AbbVieSynthroid$24,576$18,331197 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$365$6,677616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other endocrinology in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →